1 / 9

Special Blood Products

Special Blood Products. Laura Cooling MD, MS Associate Medical Director Transfusion Medicine. Over-ordering: Platelets account for 61% of all components wasted. Surgery accounts for 60% of all platelets wasted 51.5% Cardiac 3.82% Transplant 4.54% Other. Cryo 18.7%. Platelets 61%.

cora
Télécharger la présentation

Special Blood Products

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Special Blood Products Laura Cooling MD, MS Associate Medical Director Transfusion Medicine

  2. Over-ordering: Platelets accountfor 61% of all components wasted Surgery accounts for 60% of all platelets wasted 51.5% Cardiac 3.82% Transplant 4.54% Other Cryo 18.7% Platelets 61%

  3. Most Blood collected, stored in Adsol • Fraction is collected in CPD and CPDA • concern for mannitol in neonates Massive Transfusion in Neonates • Extracorporeal Membrane Oxygenation • Exchange Transfusion • Cardiovascular Surgery Adsol RBC are acceptable for routine, small transfusions in neonates

  4. Platelets: Specialty Products • Single donor apheresis platelets • Crossmatched platelets • HLA-matched platelets Pathology consult and evaluation • Patients with suspected alloimmune platelet refractoriness

  5. Irradiated Blood Products • Prevent transfusion-associated GVHD. • Engraftment donor lymphocytes • Mortality >80-90% • Cellular components only (RBC, platelets) Symptoms: • Fever • Skin eruptions • Diarrhea • Elevated LFT • Pancytopenia

  6. RELATED OR HLA-MATCHED DONOR HLA: A1, A1, B8, B8 PATIENT HLA: A1, A2, B7, B8 Patient Compatible A1, B8 Donor Incompatible A2, B7

  7. INDICATIONS • Intrauterine transfusion/exchange transfusion • Premature neonates • (<1200-1500gm and < 4 month age) • Congenital immunodeficiencies • Bone marrow transplant recipients • Hematologic malignancy • Solidtumor malignancy requiring high dose, multiagent chemotherapy • HLA-matched platelets • Directed donations from relatives ORGAN TRANSPLANTS DO NOT REQUIRE IRRADIATION

  8. Adverse Effects of Irradiation • Increased rigidity, less deformability • Contributes storage lesion (RBC) • Increased K+ leak • Decrease ATP, pH • “accelerated aging” Give irradiated components only to those patients at risk

  9. CMV-safe • Prevent TA-CMV in at-risk patients • Transmitted by lymphocytes • cellular components only (RBC, platelets) • Prevented by leukodepletion (CMV-safe) Indications: (CMV-safe) • Intrauterine transfusion • Premature infants/exchange transfusion • Bone marrow transplant • Solid organ transplant CMV-seronegative (U of M): CMV-negative BMT recipient of a CMV-negative donor

More Related